… by pronounced brain inflammation. Despite being the most common movement disorder to date, no therapy currently available can slow or halt … upon our novel preliminary findings, we will characterize how PLX5622, a compound that inhibits CSF1R, affects the …

… Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing transformative therapeutics using the ARCUSTM respiratory delivery platform, announced today the award of a grant … L-dopa compared to oral administration. CVT-301 was also shown to achieve more rapid, durable motor function …

… J. Fox Foundation for Parkinson’s Research (MJFF) announced today that it has created a Drug Discovery and Development … will provide $1.5 million in funding to validate drug targets for Parkinson’s disease. New advances in research, … legitimize various drug targets identified by the academic community. Once the drug targets are screened and validated …

… Tonight, Michael J. Fox returns to television as the star of his own sitcom after more than two decades living with Parkinson's … to television has created an opportune moment to consider how much work remains to be done in the realm of …

… NEW YORK, NY— The Michael J. Fox Foundation has committed up to $12 million in 2011 funding for prioritized research … our understanding or treatment of PD. Validating Novel Targets: Support for work demonstrating whether modulation of a …

… and Related Agencies (LHHS) appropriations bill passed by Committee on July 31, 2025 — is an important first step in … of the herbicide paraquat, which has been scientifically linked to increased Parkinson’s risk. 70 countries, … and government research funders; creates a robust open-access data set and biosample library to speed …